Synaptogenix (NASDAQ:TAOX) Posts Quarterly Earnings Results

Synaptogenix (NASDAQ:TAOX – Get Free Report) issued its quarterly earnings results on Monday. The company reported $0.38 EPS for the quarter, Zacks reports. Synaptogenix had a negative net margin of 2,153.97% and a negative return on equity of 128.51%.

Synaptogenix Stock Down 11.4%

Shares of TAOX traded down $0.24 during trading hours on Monday, reaching $1.86. The company’s stock had a trading volume of 88,871 shares, compared to its average volume of 155,319. The company has a 50 day moving average of $3.60 and a two-hundred day moving average of $4.16. The firm has a market cap of $14.96 million, a price-to-earnings ratio of -0.48 and a beta of 1.81. Synaptogenix has a 1-year low of $1.70 and a 1-year high of $7.85.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, October 15th. Wall Street Zen lowered Synaptogenix from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

View Our Latest Stock Report on Synaptogenix

About Synaptogenix

(Get Free Report)

Synaptogenix was a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases and disorders involving impaired cognitive function. The company’s research centered on therapies intended to support synaptic function. Its lead investigational drug candidate was bryostatin-1, which it studied as a potential treatment for Alzheimer’s disease. The company also explored its approach in other conditions associated with cognitive impairment. Bryostatin-1 was investigational, not an approved medicine.

Read More

Earnings History for Synaptogenix (NASDAQ:TAOX)

Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.